Global Cell & Gene Therapy Cold Chain Logistics Market Outlook, 2024-2029: Surge in Collaborations and Patient-Centric Logistics for Personalized Therapies Driving the Market at 14.1% CAGR
30 avr. 2024 04h03 HE
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapy Cold Chain Logistics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F" report has been added...
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
29 avr. 2024 06h45 HE
|
Ocugen
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
26 avr. 2024 09h05 HE
|
Ocugen
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Global Cell and Gene Therapies in Hemophilia A & B Analysis Report 2024: Market to Reach $2.2 Billion by 2029 - Major Players Are Expected To Intensify Competition
26 avr. 2024 07h22 HE
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapies in Hemophilia A & B" report has been added to ResearchAndMarkets.com's offering. The global hemophilia A and B CGT...
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
26 avr. 2024 06h30 HE
|
Ocugen
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
25 avr. 2024 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...
Gene Therapy For Ocular Rare Disease Pipeline Insight Report 2024
25 avr. 2024 04h06 HE
|
Research and Markets
Dublin, April 25, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy For Ocular Rare Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.The report provides...
Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting
23 avr. 2024 08h09 HE
|
Sania Therapeutics
Sania Therapeutics presents latest from AAV gene therapy platform at the American Society of Gene & Cell Therapy Annual Meeting Abstracts outline an approach which is highly translatable,...
U.S. Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030: Robust Pipeline and Growing Prevalence of Target Diseases Fueling Growth and Developments
23 avr. 2024 05h46 HE
|
Research and Markets
Dublin, April 23, 2024 (GLOBE NEWSWIRE) -- The "U.S. Gene Therapy Market Size, Share & Trends Analysis Report by Indication (Multiple Myeloma, Spinal Muscular Atrophy, Inherited Retinal...
Revolutionary Scientists Honored for Advancements in Gene Therapy for Neuromuscular Diseases and RNA Discoveries: King Faisal Prize Laureates in Medicine, Professor Jerry Mendell, and in Science, Professor Howard Chang, Awarded
22 avr. 2024 15h29 HE
|
King Faisal Foundation
Riyadh, Saudi Arabia, April 22, 2024 (GLOBE NEWSWIRE) -- During the 46th session of King Faisal Prize on April 22, exceptional accomplishments in the fields of gene therapy for neuromuscular...